OCULHealthcare · BiotechnologyThe 12 Wall Street analysts covering Ocular Therapeutix, Inc. hold a median 12-month price target of $28 — +281.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 14 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ocular Therapeutix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (78): Analysts have, on balance, been raising their forecasts.
Issuance (24): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OCUL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +281.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Oct 2026 | UBS | Initiates | Buy | $14 |
| 2 Oct 2026 | Chardan Capital | Maintains | Buy | $23 |
| 29 Sept 2026 | Needham | Reiterates | Buy | $18 |
| 16 Sept 2026 | Chardan Capital | Maintains | Buy | $23 |
| 16 Sept 2026 | Chardan Capital | Maintains | Buy | — |
| 16 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2026 | HC Wainwright & Co. | Reiterates | Buy | $25 |
| 4 Aug 2026 | Chardan Capital | Maintains | Buy | $23 |
| 4 Aug 2026 | Chardan Capital | Maintains | Buy | — |
| 25 June 2026 | Chardan Capital | Maintains | Buy | — |
| 25 June 2026 | Chardan Capital | Maintains | Buy | $21 → $23 |
| 18 June 2026 | Baird | Maintains | Outperform | $24 → $30 |
| 18 June 2026 | Baird | Maintains | Outperform | — |
| 18 June 2026 | HC Wainwright & Co. | Reiterates | Buy | $21 → $25 |
| 18 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2026 | RBC Capital | Reiterates | Outperform | — |
| 5 May 2026 | Needham | Reiterates | Buy | — |
| 13 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Mar 2026 | Clear Street | Maintains | Buy | — |
| 20 Feb 2026 | Needham | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCUL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Ocular Therapeutix, Inc. returned −35.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 7% of US stocks
Cheaper than 29% of US stocks
Cheaper than 78% of US stocks
Higher than 27% of US stocks
Higher than 36% of US stocks
Higher than 94% of US stocks
Higher than 7% of US stocks
Higher than 99% of US stocks
Higher than 17% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ocular Therapeutix, Inc. has a market value of $1.6B and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $52.1M. The latest quarter grew 0.1% year on year.
Net income over the same four quarters: −$301.4M, a −579.1% net margin.
Diluted earnings per share, trailing twelve months: $−1.42.
Free cash flow in the twelve months to 30 June 2026: −$255.1M.
Trailing P/E: −5.1×; forward P/E: −4.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Ocular Therapeutix, Inc. employs 325 people — $160K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Ocular Therapeutix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Ocular Therapeutix granted inducement equity awards to 15 newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan. The grants were made in connection with each recipient’s acceptance of employment and under Nasdaq Listing Rule 5635(c)(4).
Why it matters — OCUL watchers may note the equity awards as part of the company’s hiring and compensation activity.
Ocular Therapeutix announced it will participate in several scientific and investor conferences in October 2026. The company did not disclose specific conference details in the announcement.
Why it matters — OCUL watchers may gain insight into the company's retina-focused pipeline and investor positioning through its planned conference presentations.
Ocular Therapeutix stated it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what CEO Pravin Dugel described as alignment with the FDA on the planned submission package for wet age-related macular degeneration.
Why it matters — OCUL watchers would track this regulatory milestone for AXPAXLI in wet AMD, as it signals progress in the company's development pipeline.
Ocular Therapeutix announced that it granted inducement equity awards to nine newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards served as an inducement material to each recipient's acceptance of employment.
Why it matters — OCUL watchers may find this relevant as it reflects the company's hiring activity and equity compensation practices, which could be of interest for corporate governance and employee retention considerations.
Ocular Therapeutix announced the successful completion of a Pre-NDA meeting with the U.S. FDA for AXPAXLI (OTX-TKI) in wet AMD. The meeting confirmed the company's plan to submit an NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence, with submission on track for 4Q 2026 and commercial readiness accelerating ahead of a potential 2027 launch.
Why it matters — This meeting adherence moves AXPAXLI closer to NDA submission and potential approval, and the inclusion of repeat-dosing data supports the company's application for repeat dosing, a key step toward a possible first-in-class TKI for wet AMD.
The 12 Wall Street analysts covering Ocular Therapeutix, Inc. have a median 12-month price target of $28, with estimates ranging from $14 to $34. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 12 analysts covering Ocular Therapeutix, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocular Therapeutix, Inc. 37 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Ocular Therapeutix, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (78 of 100).
No one can know that. What the data says: the median 12-month target from 12 analysts implies +281.9% from the last close, and Ticker Nerd's factor model ranks Ocular Therapeutix, Inc. 37 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ocular Therapeutix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCUL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $34 over the next 12 months.
Ocular Therapeutix, Inc. returned -35.9% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye.
The most recent item we track (GlobeNewsWire, 9 Oct 2026): "Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Ocular Therapeutix granted inducement equity awards to 15 newly hired non-executive employees under its 2019 Inducement Stock Incentive Plan. The grants were made in connection with each recipient’s acceptance of employment and under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on developing and commercializing eye treatments for retinal diseases and other conditions of the eye. The company uses its proprietary bioresorbable hydrogel-based formulation technology to create sustained-release therapies designed for ophthalmic use. Its current portfolio includes a marketed product for post-surgical ocular inflammation and pain, along with investigational therapies targeting retinal diseases, glaucoma, ocular hypertension, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix’s products and pipeline are centered on improving drug delivery in ophthalmology, where longer-acting formulations can help address treatment burden and support more consistent therapy administration. Based in Bedford, Massachusetts, the company operates in the specialty biopharmaceutical market with a strong emphasis on ocular care and retinal disease management.
CEO Dr. Pravin U. Dugel M.D. · 325 employees · United States · https://www.ocutx.com
